Physician profile
Ryan Lueck
NPI 1871041566
$7,235.21
in general payments reported to CMS, 2019-2025
49 companies · $606 in 2025
The $606 reported for 2025 was more than what 77% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,195 · 2022: $2,402 · 2023: $1,235 · 2024: $1,797 · 2025: $606.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,448 · Travel and Lodging: $190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,447.83 |
| Travel and Lodging | $190.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,234.49 | 2021-2025 | |
| Livanova USA, INC. | $706.33 | 2022-2024 | Vns Therapy, Vns Therapy Sentiva Model 1000 Generator |
| Eisai INC. | $425.55 | 2021-2025 | |
| Biohaven Pharmaceuticals, INC. | $412.46 | 2021 | |
| Argenx US, INC. | $293.28 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Novartis Pharmaceuticals Corporation | $292.96 | 2023-2025 | |
| Jazz Pharmaceuticals INC. | $288.10 | 2021-2025 | |
| Genzyme Corporation | $279.64 | 2021-2025 | |
| Ucb, INC. | $277.22 | 2021-2025 | Briviact, Rystiggo |
| Pfizer INC. | $277.21 | 2021-2025 | |
| Lundbeck LLC | $237.23 | 2021-2024 | Vyepti |
| Biohaven Pharmaceutical Holding Company LTD. | $208.10 | 2022 | |
| Emd Serono, INC. | $206.27 | 2021-2025 | Mavenclad |
| Amneal Pharmaceuticals LLC | $184.07 | 2022-2025 | Rytary, Crexont |
| Acadia Pharmaceuticals INC | $165.38 | 2021-2023 | Nuplazid |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $142.43 | 2022-2024 | Ingrezza, Ongentys |
| Avion Pharmaceuticals | $136.37 | 2022-2023 | Dhivy |
| Biogen, INC. | $129.13 | 2021-2023 | Vumerity, Tysabri, Plegridy |
| Medtronic, INC. | $111.77 | 2024 | Intellis Adaptivestim |
| Amgen INC. | $108.34 | 2021-2024 | Uplizna |
| Janssen Pharmaceuticals, INC | $103.85 | 2021-2022 | |
| Acorda Therapeutics, INC | $83.03 | 2023 | Inbrija, Ampyra |
| Sk Life Science, INC. | $75.66 | 2021-2023 | |
| Tanabe Pharma America, INC. | $75.54 | 2022-2024 | |
| Supernus Pharmaceuticals, INC. | $69.64 | 2021-2022 | |
| Kyowa Kirin, INC. | $59.35 | 2021-2023 | Nourianz |
| Ani Pharmaceuticals, INC. | $53.29 | 2022-2024 | Purified Cortrophin Gel |
| Mallinckrodt Hospital Products INC. | $50.34 | 2021-2023 | Acthar |
| Solventum Corporation | $48.02 | 2025 | V.A.C. Veraflo Cleanse Choice |
| Amylyx Pharmaceuticals, INC. | $46.93 | 2023 | Relyvrio |
| Allergan, INC. | $41.98 | 2021-2022 | |
| Banner Life Sciences, LLC | $41.75 | 2021-2022 | |
| Csl Behring | $40.44 | 2022-2023 | Hizentra |
| Chiesi USA, INC. | $32.93 | 2021 | |
| Lilly USA, LLC | $31.24 | 2023-2024 | Emgality, Reyvow |
| Alexion Pharmaceuticals, INC. | $30.80 | 2022-2023 | Ultomiris |
| Teva Pharmaceuticals USA, INC. | $28.73 | 2021-2022 | |
| Horizon Therapeutics Plc | $24.99 | 2023 | Uplizna |
| Catalyst Pharmaceuticals, INC. | $23.76 | 2024 | |
| Alnylam Pharmaceuticals INC. | $20.71 | 2023 | Onpattro |
| Otsuka America Pharmaceutical, INC. | $19.67 | 2025 | Rexulti |
| Xeris Pharmaceuticals, INC. | $18.69 | 2023 | Gvoke Hypopen |
| Neurelis, INC. | $18.60 | 2021 | |
| Mdd US Operations, LLC | $17.35 | 2022 | |
| Genentech USA, INC. | $15.22 | 2022 | |
| Sunovion Pharmaceuticals INC. | $14.36 | 2022 | |
| Grifols USA, LLC | $14.21 | 2023 | Gamunex-C |
| Amicus Therapeutics, INC. | $12.55 | 2022 | |
| Corium, LLC | $5.25 | 2023 | Adlarity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Lueck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.